

Thyroid Hormone Beta Receptor Mutation Causes Renal Dysfunction and Impairment of CIC-2 Chloride Channel Expression in Mouse Kidney

Debora dos Santos Ornellas¹, Aline Cristina Gomes¹, Leticia Aragao Santiago², Horacio Javier Novaira¹, Tania Ortiga-Carvalho² and Marcelo Marcos Morales¹

¹Laboratory of Molecular and Cellular Physiology and ²Laboratory of Molecular Endocrinology, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Key Words

Thyroid hormones • $\Delta 337T$ • TR- β receptor • Thyroid hormone resistance syndrome • CIC-2 • Ion channel • Kidney

Abstract

Background/Aims: Mutations in the thyroid hormone receptor β (TR- β) gene result in resistance to thyroid hormone (RTH). Mutation $\Delta 337T$ in the TR- β gene has been shown to have the characteristics of RTH syndrome in mice. The aim of this work was to study the possible involvement of TR- β receptor in thyroid modulation of CIC-2 in mouse kidney. **Methods:** Expression of mouse ($\Delta 337T$ and normal C57BL/6) renal RNA and protein expression were studied by reverse transcriptase-polymerase chain reaction and Western blot, respectively, in mice with hyper- or hypothyroidism. Renal function was studied by analysis of urinary electrolyte excretion. Studies of the CIC-2 promoter region were performed in immortalized renal proximal tubule (IRPT) cells. **Results:** In RTH syndrome mice ($\Delta 337T$), renal dysfunction was found to be associated with changes in the fractional excretion of sodium (FE_{Na}) and chloride (FE_{Cl}). CIC-2 chloride channel mRNA and protein expression were found to be decreased by

40% in heterozygous and homozygous mutant mouse kidneys and high levels of plasma thyroid hormone were detected in both groups. Hypothyroidism induced by methimazole decreased the renal expression of CIC-2 in normal mice but not in $\Delta 337T$ mutant mice. In *in vitro* studies performed on IRPT cells subjected to thyroid hormone treatment, the promoter region of the CIC-2 chloride channel was stimulated in a dose-dependent manner. **Conclusions:** This work emphasizes the importance of thyroid hormone in electrolyte handling along the nephron and suggests its participation in renal CIC-2 gene transcription via the TR- β receptor pathway.

Copyright © 2010 S. Karger AG, Basel

Introduction

Several isoforms of the CLC family of voltage-gated chloride channels are involved in several physiological functions in human tissues. Mutations in some of these isoforms cause human hereditary diseases. Mutation in: (a) CIC-1, the major skeletal muscle chloride channel leads to myotonia [1, 2]; (b) CIC-K, a kidney-specific chloride channel, leads to either nephrogenic diabetes insipidus or Bartter syndrome [2, 3]; and (c) CIC-5 leads to Dent

disease [2, 4]. CIC-2 is a member of the CLC family and is broadly expressed in a variety of tissues [5], however, its function has not been fully elucidated. CIC-2 was found to be important in the fetal stage of lung development [6] and disruption of this chloride channel in knockout mice was found to lead to a degeneration of the seminiferous tubule of the testis and the retina [7]. These findings strongly suggest its participation in secretory processes in epithelia.

CIC-2 is abundantly expressed in the kidney and the channel is activated by different stimuli commonly found in the renal environment, such as: (a) membrane hyperpolarization [8]; (b) increase in cellular volume [9]; (c) a decrease in extracellular pH [10]; and (d) increase in intracellular chloride concentrations [10].

Our group have shown that CIC-2 is modulated by vasopressin and aldosterone in rat kidney indicating the importance of this channel in the transport of chloride modulated by hormones classically involved in the regulation of extracellular fluid volume [11, 12]. We also found that other hormones, such as estrogen, can lead to significant increase in renal CIC-2 expression, mainly in proximal tubules.

Thyroid hormones, triiodothyronine (T_3) and thyroxine (T_4) are important in renal physiology and their actions are mediated by high affinity to nuclear thyroid hormone receptors (TRs) that bind T_3 . There are several T_3 -binding TR isoforms ($\beta 1$, $\beta 2$, $\beta 3$, $\Delta\beta 3$, $\alpha 1$) and isoforms that do not bind T_3 ($\alpha 2$, $\Delta\alpha 1$ and $\Delta\alpha 2$) derived from α - and β -TR genes by alternative splicing of the primary transcripts or derived from alternative promoters [13,14]. TR mRNA expression depends on development and cellular differentiation [15]. TR- $\alpha 1$, TR- $\alpha 2$ and TR- $\beta 1$ mRNAs are expressed in most tissues, including the kidney. TR- $\beta 1$ is most abundantly expressed in liver, kidney and brain; TR- $\beta 2$ is expressed mainly in the pituitary gland and other sites in the brain [15]. Rat TR- $\beta 3$ is expressed mainly in the liver, kidneys and lungs. Mutations in the TR- β gene generate mutant receptors with impaired binding of T_3 causing the human syndrome of resistance to thyroid hormone (RTH) [16, 17]. Transgenic mice generated by mutation in TR- β present characteristics similar to human RTH, such as high levels of T_3 , T_4 and thyroid-stimulating hormone (TSH), hyperplastic thyroid gland, increased basal heart frequency and inner ear defects, and is a excellent model to study the action of thyroid hormones [17–19].

It is well known that thyroid hormones are important for renal morphology and function [20] and they are essential for kidney growth and development. Thyroid

deficiencies can result in decreased renal plasma flow and glomerular filtration rate (GFR), as well as impaired urinary concentration and dilution [20]. A decrease in distal tubule delivery of chloride was found in patients with hyperthyroid Graves disease [21]. Previous studies from our group have shown that CIC-2 chloride channel gene expression is modulated by thyroid hormone [22] but the mechanisms involved in this phenomenon remain unclear. The main goal of the present work was to study the possible involvement of TR- β receptor in thyroid modulation of CIC-2 in the kidney and possible involvement of this channel promoter region in this process.

Materials and Methods

Animal treatment

Male adult 129/C57BL/6 strain mice weighing 20–25 g (from Laboratory of Molecular Endocrinology, IBCCf, UFRJ) were used. Animals were kept in a room with controlled lighting (12-h light/12-h dark, lights on at 7:00 a.m., lights off at 7:00 p.m.) and temperature (23–26°C) with free access to food and tap water. All animal experiments were performed according to the NIH Guidelines for the Care and Use of Laboratory Animals and protocols were approved by our institutional animal ethics committee. Hypothyroidism was induced in 129/C57BL/6 mice (Hypo group) by the addition of 0.1% methimazole (MMI; Sigma Chemical Co., St. Louis, MO, USA), an inhibitor of the synthesis and release of 3,5,3'-L-triiodothyronine and thyroxine (T_3 and T_4 , respectively) [23], to the drinking water for 45 days. The Hypo+ T_4 group of animals were Hypo mice subjected to daily subcutaneous injections of thyroxine (1 μ g /100 g body weight (BW); Sigma) for 15 days before sacrifice. The Hypo group received subcutaneous injections of saline for the last 15 days before sacrifice.

Hyperthyroidism was induced by daily subcutaneous injection of thyroxine (10 μ g /100 g BW; Sigma) in normal animals for 15 days (Hyper group).

All animals were killed by decapitation 18 h after the last injections and blood samples were then collected for hormonal evaluation [23]. TR- β ($\Delta 337T$) mutated mice, homozygous (Homo group) or heterozygous (Hetero group), were provided by Molecular Endocrinology Laboratory, Federal University of Rio de Janeiro. These mutated animals were generated by Dr Fredric E. Wondisford's group, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. This mutation avoids the TR binding to T_3 . TR- β ($\Delta 337T$) mutated homozygous and heterozygous mice were subjected to treatment with MMI as described above and the groups were identified as the Homo MMI group and the Hetero MMI group, respectively.

Radioimmunoassay

Plasma T_4 was measured by radioimmunoassay using specific antibodies (Kit Coat A Count, Diagnostic Products Cor-

poration, Los Angeles, USA), according to the manufacturer's suggested protocol.

Isolation of total RNA

Total RNA was extracted from kidney or cell cultures using Trizol® reagent (Invitrogen, BRL, Grand Island, NY, USA), following the manufacturer's suggested protocol. Purified total RNA was treated with 1 U/μl of ribonuclease (RNase)-free deoxyribonuclease (DNase) I (GIBCO BRL, Grand Island, NY, USA) for 30 min to eliminate any genomic DNA contamination.

Reverse transcription-polymerase chain reaction (RT-PCR)

RT-PCR analysis was carried out on 500 ng of total RNA using reverse transcriptase SuperScript™ (GIBCO BRL, Grand Island, NY, USA).

To prepare first-strand deoxyribonucleic acid (cDNA), total RNA samples isolated from whole kidney were first primed with oligo-deoxythymidylic (oligo dT) primer and then reverse-transcribed with SuperScript (Gibco BRL, Grand Island, NY, USA) at 37°C for 60 min. PCR amplification of the synthesized cDNA was carried out under the following reaction conditions: 0.2 mmol/l of the primers, 0.2 mmol/l of each deoxynucleotide triphosphate (dNTP) and 50 mmol/l of KCl, 10 mmol/l of Tris–Cl (pH 8.3) and 1.5 mmol/l of MgCl₂ plus 2.5 U of Amplitaq (Perkin Elmer, New Jersey, USA). Primers for CIC-2 (sense 5'-CTA TGC CAT CGC GTC TG-3' and antisense 5'-GAA GTC GAG TCG GAA CCG-3') GenBank accession no. X64139 [5], respectively, were synthesized. PCR cycling parameters were: 35 cycles of denaturation (94°C, 1 min), annealing (55°C, 1 min) and extension (72°C, 1 min). Primers for rat CIC-2 were used after searching for homology in the BLAST program (GenBank accession no. BC137625.1). Preliminary experiments validated the semi-quantitative RT-PCR methods used as described previously [22, 24].

Semi-quantitative RT-PCR was used to compare the expression of CIC-2 in each of the following groups: (1) control, (2) hypothyroid (Hypo), (3) hypothyroid replaced with thyroxine (Hypo + T₄), (4) hyperthyroid (Hyper), (5) heterozygous, (6) (Hetero), (7) homozygous (Homo), (8) control treated with MMI, (9) heterozygous treated with MMI (Hetero MMI), (10) homozygous treated with MMI (Homo MMI). PCR conditions were the same as those described earlier, with the addition of mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene primers (sense 5'-CAA CCA ACT TGC TTA GCC C-3' and antisense 5'-GCT CTG GGA TGA CCT TGC-3', corresponding to nucleotides and amplifying a predicted internal control product of 206 bp, GenBank accession no. XM_906931) to the same RT-PCR reaction tubes. CIC-2 and GAPDH bands amplified in the same sample were analyzed by densitometry and normalized by dividing the target gene values by the corresponding GAPDH values. Sigma Gel v1.1 (Jandel Scientific, Corte Madera, CA, USA) software was used for densitometric analysis of the bands.

Western blot analysis

Expression of CIC-2 protein in whole mouse kidney from different groups of animals was assessed and compared by

immunoblotting using an antibody directed towards a synthetic peptide corresponding to amino acids 808–906 of the rat CIC-2 (Sigma-RBI, USA). This antibody specifically recognizes CIC-2 protein [5]. Kidneys from all mouse groups were homogenized and protein was obtained as described previously [25]. Membrane proteins (200 μg/lane) were subjected to 70 g/l sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to 0.45-mm Immobilon-NC nitrocellulose membranes (Sigma). We used rabbit anti-CIC-2 antibody (1:300 dilution) diluted in Tris-buffered saline (TBS, pH 7.4) solution plus 0.5% Tween 20 (TBS-T solution) containing 30 g/l non-fat milk (TBS-T+milk) at room temperature for 1 h. The specificity of this antibody has been reported previously [5]. Subsequent to incubation with a 1:1000 dilution of the alkaline phosphatase-labeled secondary antibody goat anti-rabbit IgG (H+L), detection was performed by exposure to an alkaline phosphatase substrate containing 75 mg/ml of nitroblue tetrazolium chloride (NBT) and 50 mg/ml of 5-bromo-4-chloro-3-indolylphosphate *p*-toluidine salt (BCIP) (all from Life Technologies, Rockville, MD, USA) for 5 min. To rule out the possibility of non-specific secondary antibody binding, the same experiment was performed in the absence of rabbit-anti-CIC-2; no bands were detected under these conditions.

DNA transfection and CIC-2 promoter region

Immortalized renal proximal tubule (IRPT) cells were grown to confluence and the day before transfection, cells were detached by exposure to 0.05% trypsin in Ca²⁺- and Mg²⁺-free solution, reseeded in 6-well plates, reaching 70% confluence on the day of transfection. The cells were transiently co-transfected with 2.0 μg of CIC-2 rat promoter construct plasmid DNA [26] (kindly provided by Dr P. Zeitlin, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA) [27] for the luciferase reporter assay and 2.0 μg of pSV-galactosidase plasmid diluted in 250 μl D-MEM without serum or antibiotic, using 6 ml of Lipofectamine 2000 reagent (Invitrogen) diluted in 250 μl D-MEM without serum and antibiotic added to the cells in a final volume of 500 μl per well. Cells were incubated at 37°C for 3 h. The medium was then removed and 2 μl of supplemented D-MEM were added per well. The cells were cultured for 24 h. After this period, the cells were washed and treated with triiodothyronine 10⁻⁷ M, 10⁻⁶ M, 10⁻⁵ M for 24 h at 37°C. Cells were washed twice with 3 ml of phosphate buffered saline (PBS) and then lysed in 250 μl (per well) with lysis buffer (25 mM gly-gly, 15 mM MgSO₄, 4 mM EGTA, Triton X (25%) and 1 mM DTT) for 20 min at room temperature. Luciferase activity was quantified using 200 ml of cell lysates, 100 ml of D-luciferin (Molecular Probes Inc., Eugene, OR, USA) and 100 μl of luciferase assay buffer (25 mM gly-gly, 15 mM MgSO₄, 4 mM EGTA, 15 mM KH₂PO₄, 6 mM ATP and 3 mM DTT) per sample. Light emission was detected using a TD-20/20 luminometer (Turner Designs) for 30 s at room temperature. β-Galactosidase activity utilized for the normalization of the results, was quantified using 30 μl of cell lysates, 160 μl of 2-nitrophenyl-β-D-galactopyranoside (ONPG) reagent (60 mM Na₂HPO₄, 40 mM NaH₂PO₄ and 2 mg/ml of ONPG) and 810 μl of buffer β-gal (60 mM Na₂HPO₄,

	Control	Hetero	Homo
GFR ($\mu\text{l}/\text{min}$ per g KW)	755 \pm 107.82	820 \pm 68.8	710 \pm 85.83
FE _{Na} (%)	0.79 \pm 0.01	0.63 \pm 0.08	1.22 \pm 0.08*
FE _K (%)	11.04 \pm 1.71	10.27 \pm 1.25	10.83 \pm 0.89
FE _{Cl} (%)	0.83 \pm 0.04	0.83 \pm 0.04	1.41 \pm 0.08*
Urine flux ($\mu\text{l}/\text{g}$ BW per 24 h)	88.12 \pm 1.1	86.25 \pm 2.4	85.87 \pm 2.57

Table 1. Comparison of renal functional characteristics of TR- β mutated mice. Normal 129/C57BL/6 (Control); homozygous (Homo) and heterozygous (Hetero) for thyroid hormone receptor β ; KW, kilogram weight; BW, body weight; FE, fractional excretion. *Significantly different from control; $p < 0.05$.

Fig. 1. Modulation of CIC-2 mRNA and protein by thyroid hormones. (A) Expression of CIC-2 mRNA in the kidney of control, hypo- and hyperthyroid mice according to semi-quantitative RT-PCR analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and GAPDH bands obtained in RT-PCR experiments. (B) Expression of CIC-2 protein in the kidney of control, hypo- and hyperthyroid mice according to Western blot analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and β -actin bands obtained in Western blot experiments. Hypothyroid mice were treated with saline (Hypo) or 1 μg thyroxine/100 g BW (Hypo+T₄) for 15 days. The Hyper group were normal mice receiving T₄ (10 μg /100 g BW) for 15 days. * $p < 0.05$. Statistically different from control ($n=5$).

40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgCl₂ and 50 mM β -mercaptoethanol) at 420 nm.


Statistical analysis

ANOVA followed by the Newman-Keuls multiple comparison test was used to compare differences between groups. Results are presented as means \pm SE. Differences were assumed to be significant when $p \leq 0.05$.

Results

T₄ plasma levels

The T₄ plasma level for the control group was 4.29 \pm 0.41 $\mu\text{g}/\text{dl}$ ($n=6$). Hypothyroid animals showed nearly undetectable levels of T₄ (0.01 \pm 0.00, $n=5$, $p < 0.05$). Treatment of hypothyroid mice with a physiological dose of thyroxine (1 $\mu\text{g}/100$ g BW per day; 15 days) normalized T₄ levels. Animals treated with ten-fold higher doses of T₄ (Hyper group) developed hyperthyroidism (6.43 \pm 0.95 $\mu\text{g}/\text{dl}$, $n=6$, $p < 0.05$). In heterozygous TR- β mutated mice, the plasma level of T₄ was 4.9 \pm 0.41 $\mu\text{g}/\text{dl}$ ($n=6$, $p < 0.05$) and for homozygous animals the level was >20 $\mu\text{g}/\text{dl}$ ($n=6$, $p < 0.05$).



Renal function

TR- β mutated mice showed no changes in GFR, urinary flow and fractional excretion of potassium between mutated (heterozygous and homozygous) and control groups. The heterozygous mice showed no changes in the parameters analyzed, showing renal function similar to that of normal animals. However, the fractional excretion of Na⁺ and Cl⁻ was increased compared with control mice homozygous for the mutation of receptor β (1.215 \pm 0.083 and 1.413 \pm 0.079), respectively ($n=10$, $p < 0.05$) (Table 1).

CIC-2 chloride channel expression

To test and quantify the influence of thyroid hormones on CIC-2 mRNA expression in mice kidney, we




Fig. 2. Modulation of CIC-2 mRNA and protein in the kidney of TR- β mutated mice. (A) Expression of CIC-2 mRNA in the kidney of control, heterozygous and homozygous mice according to semi-quantitative RT-PCR analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and GAPDH bands obtained in RT-PCR experiments. (B) Expression of CIC-2 protein in the kidney of control, Hetero and Homo mice according to Western blot analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and β -actin bands obtained in Western blot experiments. (1) Control (C), (2) heterozygous (Hetero), (3) homozygous (Homo). * p <0.05. Statistically different from control (n =5).




Fig. 3. Modulation of CIC-2 mRNA and protein in kidney of TR- β mutated mice (heterozygous and homozygous) treated with methimazole compared with the control group. (A) Expression of CIC-2 mRNA in the kidney of control, Hetero and Homo mice according to semi-quantitative RT-PCR analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and GAPDH bands obtained in RT-PCR experiments. (B) Expression of CIC-2 protein in kidney of control, Hetero and Homo mice according to Western blot analysis. Graphs represent the mean \pm SEM for the ratio between the densitometric values of CIC-2 and β -actin bands obtained in Western blot experiments. Control (C) was used to compare the expression of CIC-2 in each of the following groups: control (C) treated with methimazole (MMI); mutated mice (heterozygous (Hetero) and homozygous (Homo)) both treated with methimazole. * p <0.05. Statistically different from control.

used semi-quantitative RT-PCR. We observed 615 bp bands, corresponding to CIC-2 in all analyzed groups. Densitometric analysis of the bands corresponding to CIC-2 and normalized by GAPDH mRNA showed that hypothyroid animals presented a decrease in CIC-2 renal expression compared with control levels (75% of control) (n =6, p <0.05, Fig. 1A). Treatment of hypothyroid mice with a physiological dose of thyroxine (1 μ g/100 g of BW/day) for 15 days normalized the amount of CIC-2 mRNA renal expression to control levels. Treatment of

normal mice with a supraphysiological dose of T_4 (10 μ g/100 g of BW per day) for 15 days induced an increase in CIC-2 renal mRNA expression compared with control animals (35% of control) (n =5; p <0.05, Fig. 1A). As shown in Fig. 1B, CIC-2 protein expression presented a similar pattern of expression modulation compared with that observed at the mRNA level. Lack of thyroid hormone caused a 70% decrease in CIC-2 protein expression compared with control animals (n =5; p <0.05, Fig. 1B). CIC-2 protein levels were normalized with the physi-




Fig. 4. Modulation of the CIC-2 chloride channel gene promoter region in IRPT cells by T_3 . Graph shows luciferase activity in transfected IRPT cells without T_3 (control); or treated with 10^{-9} , 10^{-8} , 10^{-7} , 10^{-6} and, 10^{-5} M T_3 . Luciferase activity was normalized by co-transfection with pSV- β -galactosidase plasmid ($n=5$). * $p<0.0001$ versus control.

ological dose of T_4 and were increased after the supraphysiological dose of thyroxine (22% of control, $n=5$; $p<0.05$, Fig. 1B).

In the studies on TR- β mutated mice, it was found that CIC-2 mRNA expression was less expressed in kidneys of the heterozygous (41% of control) and homozygous (45% of control) groups ($p<0.001$, $n=5$, Fig. 2A). CIC-2 renal protein expression analyzed by Western blot showed a decrease in the heterozygous (48% of control) and homozygous (46% of control) groups ($p<0.001$, $n=5$) compared with the control group (Fig. 2B). In addition to investigating CIC-2 chloride channel expression in TR- β mutated mice (homozygous and heterozygous), we treated the two groups of animals with MMI. We observed a similar decrease in renal CIC-2 mRNA expression in heterozygous (43% of control) and homozygous (40% of control) mice when they were treated with MMI, compared with control levels ($p<0.001$, $n=3$) (Fig. 3A). When CIC-2 renal protein expression was studied in MMI-treated heterozygous and homozygous mice, a decrease was observed in both groups (54% and 55% of control levels, respectively; $p<0.001$, $n=4$) (Fig. 3B).

CIC-2 promoter region analysis

The luciferase reporter gene assay suggests that T_3 is capable of modulating the CIC-2 gene promoter re-

gion. IRPT cells transfected with the plasmid containing the CIC-2 promoter region associated with the luciferase gene presented enzyme activity, indicating a successful transient transfection. Transfected cells treated with 10^{-9} M, 10^{-8} M, 10^{-7} M, 10^{-6} M, 10^{-5} M of T_3 led to an increase in luciferase activity of 51%, 40%, 45%, 49% and 49% ($p<0.001$, $n=6$) compared with transfected cells with no hormone treatment (control) (Fig. 4).

Discussion

The regulation of NaCl transport in the kidney is essential for the maintenance of extracellular fluid and blood pressure [27]. Most of these renal transporters are regulated by classic hormones such as aldosterone, atrial natriuretic peptide and vasopressin. Several studies have investigated the role of these hormones in the modulation of sodium (the most abundant ion in extracellular fluid) transport along the nephron. Although chloride is the major anion present in the extracellular compartment, it is not a frequent focus of hormonal regulation studies in the kidney; especially by those not classically involved in extracellular volume regulation, such as thyroid hormones.

Chloride transport along the nephron occurs mainly by the paracellular pathway [28, 29] but an important part is transported transcellularly via chloride channels. Among the many chloride channels, we highlight the CLC family of chloride channels, especially CIC-2, with high expression in the kidney. In addition, CIC-2 has characteristics that are attractive for renal physiology, such as: (a) activation by hyperpolarization of cell membrane; (b) increase in intracellular volume; (c) decrease in extracellular pH; and (d) increase in intracellular chloride concentration [2, 30]. All these characteristics are similar to those found in the interstitial space that surrounds the epithelial cells of the renal tubules (nephron) and they are altered by different hormones that can modulate renal transport such as thyroid hormones.

Thyroid hormones can affect several aspects of renal function participating in hydroelectrolytic equilibrium control. Thyroid hormones can increase fluid reabsorption in mouse proximal tubules [20, 31-32] and modulation of different ion transporters such as Na^+/H^+ was observed in the same segment of nephron [32]. At the molecular level, the expression of mRNA and protein and the activity of renal Na^+/K^+ -ATPase are increased by thyroid hormones [20]. In addition, the rate of absorption of chloride in the proximal tubule was found to be diminished in studies of perfusion of proximal tubule in hy-

pothyroid rabbits [29] showing that this modulation is preserved among different species. In a previous publication, our group observed that rat renal CIC-2 mRNA and protein are modulated by thyroid hormones essentially in the proximal tubule in vivo and in vitro [22] although the mechanisms involved in this action were not elucidated. In the present work, we were able to elucidate part of the mechanism of action involved in thyroid hormone modulation of renal expression of the CIC-2 channel. It is well known that thyroid hormone modulates gene expression via thyroid hormone nuclear receptors, TR- α and TR- β , and the complex hormone receptor recognizes consensus sequences (thyroid hormone responsive elements [TREs]) in promoter regions of several genes and can repress or activate gene transcription [18, 22]. Analysis of the CIC-2 promoter region sequence showed three possible sequences with homology that varied between 50 and 70% of TREs. The observation that the CIC-2 promoter region was stimulated by T₃ in the IRPT cells (Fig. 4) strongly suggests the action of this hormone at transcription levels. In addition, hypothyroidism induced in mice led to a reduction in the expression of CIC-2 mRNA (Fig. 1A) and protein (Fig. 1B) expressions, and replacement of thyroid hormone in hypothyroid animals brought the level of CIC-2 renal expression to that of the controls. Hyperthyroid animals had increased renal expression of CIC-2 mRNA (35%) and protein (22%) compared with controls (Fig. 1). The pattern of expression modulation of renal CIC-2 by thyroid hormones was similar to that found for rats [22], corroborating the hypothesis that the physiological role of thyroid hormones in the kidney is conserved among different species. The possible involvement of TR- β in thyroid hormone renal modulation of CIC-2 was investigated using TR- β mutated animals (which present a syndrome of resistance to the thyroid hormone), which led to hyposensitivity to thyroid

hormone. This syndrome is characterized mainly by high levels of serum T₃ and T₄ and inappropriate levels of TSH (increased in most cases). We observed that TR- β mutated mice, heterozygous or homozygous, presented decreased expression of CIC-2 renal mRNA (Fig. 2A) and protein (Fig. 2B) compared with wild type animals. This similar pattern of expression of CIC-2 mRNA and protein found for homozygous and heterozygous mice in kidney could be secondary to a phenomenon called dominant negative regulation by the mutant receptor, in which the mutant thyroid hormone receptor interferes with the function of the normal receptor in the regulation of target genes [33]. The dysfunction of TR- β receptor can also interfere with other chloride transporters such as the chloride channel CFTR [34]. This channel is a modulator of other transporters, including sodium and chloride, and could contribute to the reduction in FE_{Na} and FE_{Cl} observed in our results [35] (Table 1). In addition, many other chloride channels are expressed in the kidney and their expression could also be modulated in the absence of TR- β receptor in mutated mice causing the decrease in renal FE of Cl⁻.

The high levels of T₃ and T₄ and TSH found in heterozygous and homozygous animals could lead to misinterpretation of the results because the increased plasma levels of hormones could modulate other proteins and/or factors that may modulate CIC-2 expression in the kidney. The treatment of TR- β mutated animals with MMI minimized this hypothesis because the levels of renal CIC-2 mRNA (Fig. 3A) and protein (Fig. 3B) were not different compared with animals not subjected to MMI treatment (heterozygous and homozygous).

We conclude that TR- β isoform is involved in the mechanism of action of thyroid hormone expression of the renal CIC-2 chloride channel via the CIC-2 promoter region of the gene.

References

- 1 Mankodi A: Myotonic disorders. *Neurol India* 2008;56:298-304.
- 2 Waldegger S, Jentsch TJ: From tonus to tonicity: physiology of CLC chloride channels. *J Am Soc Nephrol* 2000;11:1331-1339.
- 3 Scholl U, Hebeisen S, Janssen AG, Muller-Newen G, Alekov A, Fahlke C: Barttin modulates trafficking and function of CIC-K channels. *Proc Natl Acad Sci USA* 2006;103:11411-11416.
- 4 Knohl SJ, Scheinman SJ: Inherited hypercalciuric syndromes: Dent's disease (CLC-5) and familial hypomagnesemia with hypercalciuria (paracellin-1). *Semin Nephrol* 2004;24:55-60.

- 5 Thiemann A, Grunder S, Pusch M, Jentsch TJ: A chloride channel widely expressed in epithelial and non-epithelial cells. *Nature* 1992;356:57-60.
- 6 Murray CB, Morales MM, Flotte TR, McGrath-Morrow SA, Guggino WB, Zeitlin PL: CIC-2: a developmentally dependent chloride channel expressed in the fetal lung and downregulated after birth. *Am J Respir Cell Mol Biol* 1995;12:597-604.
- 7 Bosl MR, Stein V, Hubner C, Zdebik AA, Jordt SE, Mukhopadhyay AK, Davidoff MS, Holstein AF, Jentsch TJ: Male germ cells and photoreceptors, both dependent on close cell-cell interactions, degenerate upon CIC-2 Cl(-) channel disruption. *EMBO J* 2001;20:1289-1299.
- 8 Pusch M, Jordt SE, Stein V, Jentsch TJ: Chloride dependence of hyperpolarization-activated chloride channel gates. *J Physiol* 1999;515(Pt 2):341-353.
- 9 Xiong H, Li C, Garami E, Wang Y, Ramjeesingh M, Galley K, Bear CE: CIC-2 activation modulates regulatory volume decrease. *J Membr Biol* 1999;167:215-221.
- 10 Jordt SE, Jentsch TJ: Molecular dissection of gating in the CIC-2 chloride channel. *EMBO J* 1997;16:1582-1592.
- 11 Ornellas DS, Nascimento DS, Christoph DH, Guggino WB, Morales MM: Aldosterone and high-NaCl diet modulate CIC-2 chloride channel gene expression in rat kidney. *Pflugers Arch* 2002;444:193-201.
- 12 Morales MM, Nascimento DS, Capella MA, Lopes AG, Guggino WB: Arginine vasopressin regulates CFTR and CIC-2 mRNA expression in rat kidney cortex and medulla. *Pflugers Arch* 2001;443:202-211.
- 13 Flamant F, Samarut J: Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. *Trends Endocrinol Metab* 2003;14:85-90.
- 14 Sadow PM, Chassande O, Koo EK, Gauthier K, Samarut J, Xu J, O'Malley BW, Weiss RE: Regulation of expression of thyroid hormone receptor isoforms and coactivators in liver and heart by thyroid hormone. *Mol Cell Endocrinol* 2003;203:65-75.
- 15 Lazar MA: Thyroid hormone receptors: multiple forms, multiple possibilities. *Endocr Rev* 1993;14:184-193.
- 16 Refetoff S, Weiss RE, Usala SJ: The syndromes of resistance to thyroid hormone. *Endocr Rev* 1993;14:348-399.
- 17 Refetoff S: Resistance to thyroid hormone. *Clin Lab Med* 1993;13:563-581.
- 18 Cheng SY: Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. *Trends Endocrinol Metab* 2005;16:176-182.
- 19 Hashimoto K, Curty FH, Borges PP, Lee CE, Abel ED, Elmquist JK, Cohen RN, Wondisford FE: An unliganded thyroid hormone receptor causes severe neurological dysfunction. *Proc Natl Acad Sci U S A* 2001;98:3998-4003.
- 20 Katz AI, Emmanouel DS, Lindheimer MD: Thyroid hormone and the kidney. *Nephron* 1975;15:223-249.
- 21 Shiota T, Shinoda T, Aizawa T, Mizukami T, Katakura M, Takasu N, Yamada T: Primary hypothyroidism and multiple endocrine failure in association with hemochromatosis in a long-term hemodialysis patient. *Clin Nephrol* 1992;38:105-109.
- 22 Santos Ornellas D, Grozovsky R, Goldenberg RC, Carvalho DP, Fong P, Guggino WB, Morales M: Thyroid hormone modulates CIC-2 chloride channel gene expression in rat renal proximal tubules. *J Endocrinol* 2003;178:503-511.
- 23 Ortega-Carvalho TM, Polak J, McCann S, Pazos-Moura CC: Effect of thyroid hormones on pituitary neuromedin B and possible interaction between thyroid hormones and neuromedin B on thyrotropin secretion. *Regul Pept* 1996;67:47-53.
- 24 Nascimento DS, Reis CU, Goldenberg RC, Ortega-Carvalho TM, Pazos-Moura CC, Guggino SE, Guggino WB, Morales MM: Estrogen modulates CIC-2 chloride channel gene expression in rat kidney. *Pflugers Arch* 2003;446:593-599.
- 25 Park CW, Shin YS, Ahn SJ, Kim SY, Choi EJ, Chang YS, Bang BK: Thyroxine treatment induces upregulation of renin-angiotensin-aldosterone system due to decreasing effective plasma volume in patients with primary myxoedema. *Nephrol Dial Transplant* 2001;16:1799-1806.
- 26 Chu S, Blaisdell CJ, Liu MZ, Zeitlin PL: Perinatal regulation of the CIC-2 chloride channel in lung is mediated by Sp1 and Sp3. *Am J Physiol* 1999;276:L614-L624.
- 27 Guyton AC: Kidneys and fluids in pressure regulation. Small volume but large pressure changes. *Hypertension* 1992;19:12-18.
- 28 Dantzer WH: Regulation of renal proximal and distal tubule transport: sodium, chloride and organic anions. *Comp Biochem Physiol A Mol Integr Physiol* 2003;136:453-478.
- 29 Aronson PS, Giebisch G: Mechanisms of chloride transport in the proximal tubule. *Am J Physiol* 1997;273:F179-F192.
- 30 Jentsch TJ, Maritzen T, Zdebik AA: Chloride channel diseases resulting from impaired transepithelial transport or vesicular function. *J Clin Invest* 2005;115:2039-2046.
- 31 Capasso G, De Tommaso G, Pica A, Anastasio P, Capasso J, Kinne R, De Santo NG: Effects of thyroid hormones on heart and kidney functions. *Miner Electrolyte Metab* 1999;25:56-64.
- 32 Incerpi S, Scapin S, D'Arezzo S, Spagnuolo S, Leoni S: Short-term effects of thyroid hormone in prenatal development and cell differentiation. *Steroids* 2005;70:434-443.
- 33 Chatterjee VK, Nagaya T, Madison LD, Datta S, Rentoumis A, Jameson JL: Thyroid hormone resistance syndrome. Inhibition of normal receptor function by mutant thyroid hormone receptors. *J Clin Invest* 1991;87:1977-1984.
- 34 de Andrade Pinto AC, Barbosa CM, Ornellas DS, Novaira HJ, de Souza-Menezes J, Ortega-Carvalho TM, Fong P, Morales MM: Thyroid hormones stimulate renal expression of CFTR. *Cell Physiol Biochem* 2007;20:83-90.
- 35 Huber R, Krueger B, Diakov A, Korbacher J, Haerteis S, Einsiedel J, Gmeiner P, Azad AK, Cuppens H, Cassiman JJ, Korbacher C, Rauh R: Functional characterization of a partial loss-of-function mutation of the epithelial sodium channel (ENaC) associated with atypical cystic fibrosis. *Cell Physiol Biochem* 2010;25:145-158.